Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Current Deferred Revenue: 2009-2025

Historic Current Deferred Revenue for Cytokinetics (CYTK) over the last 7 years, with Sep 2025 value amounting to $1.6 million.

  • Cytokinetics' Current Deferred Revenue was N/A to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year change of. This contributed to the annual value of $52.4 million for FY2024, which is N/A change from last year.
  • Per Cytokinetics' latest filing, its Current Deferred Revenue stood at $1.6 million for Q3 2025, which was up 19.94% from $1.3 million recorded in Q2 2025.
  • In the past 5 years, Cytokinetics' Current Deferred Revenue ranged from a high of $52.4 million in Q4 2024 and a low of $1.3 million during Q2 2025.
  • Over the past 2 years, Cytokinetics' median Current Deferred Revenue value was $27.0 million (recorded in 2024), while the average stood at $26.9 million.